LSP 7 Cooperative UA 4
4 · Evommune, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
LSP 7 Cooperative UA
Director10% Owner
Transactions
- Purchase
Common Stock
2025-11-07$16.00/sh+1,562,500$25,000,000→ 4,929,633 total - Conversion
Common Stock
2025-11-07+3,367,133→ 3,367,133 total - Conversion
Series A Preferred Stock
2025-11-07−15,493,466→ 0 total→ Common Stock (1,947,477 underlying) - Conversion
Series B Preferred Stock
2025-11-07−5,090,000→ 0 total→ Common Stock (646,587 underlying) - Conversion
Series C Preferred Stock
2025-11-07−6,585,011→ 0 total→ Common Stock (773,069 underlying)
Footnotes (4)
- [F1]Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
- [F2]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
- [F3]Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F4]The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.